|Biography Articles Advise & Dissent Books Book Him! Search Contact Home|
By Michael Fumento
Makers of the MS drug Tysabri, Elan and Biogen Idec, have announced that no new cases of multifocal leukoencephalopathy (PML) have been found in patients, formerly on Tysabri, in clinical trials for the treatment of Crohn's disease and rheumatoid arthritis. This completes the review of all 3,000 patients on Tysabri. The companies had already requested permission from the FDA to return the drug to the market and are now awaiting the agency's response to their request for a priority review. I wrote one column asking for a sane, compassionate approach to the appraisal of Tysabri and another, after more data had come in, calling for the drug's return. This is exciting stuff for those with MS, other autoimmune disease like Crohn's and rheumatoid arthritis, and anybody who has loved ones who have or will develop these diseases. That makes just about all of us.
October 17, 2005 09:44 PM · Pharmaceuticals
Syndication FeedsRSS 1.0
Movable Type 3.33
Site design by